CDMO & Manufacturing

Richter BioLogics is a Germany-based CDMO specializing in microbial production of biologics from bacteria and yeasts, including recombinant proteins, peptides, VHH/nanobodies, plasmid DNA, and bacterial vaccines. It offers cGMP-compliant services from cell line and process development to commercial manufacturing across fermenter scales of 10L to 1,500L in three facilities. With over 35 years of experience, the company supports E. coli, P. pastoris, cell-free systems, and additional strains.

Selkirk Pharma is a US-based contract manufacturing organization specializing in sterile fill/finish of injectable drug products, including vaccines and biologics, for clinical trials and commercial manufacturing. The company operates a state-of-the-art, APS-qualified facility in Spokane, Washington, offering services like aseptic fill/finish, analytical testing, manual inspection, and logistics. Founded in 2018 by industry experts, it provides scalable solutions through its proprietary ClinFAST program for rapid clinical trial material delivery.

Fortis Life Sciences provides custom design, validation, and manufacturing solutions for diagnostics and life science organizations, acting as an extension of technical and R&D teams. The company offers capabilities across antibodies, diagnostic components, molecular biology reagents, engineered nanoparticles, and viral vector platforms. They specialize in process development for ultra-sensitive quantitative diagnostic assays and components like quality control materials and blood separation solutions to streamline workflows.

Freudenberg Medical is a global CDMO partner specializing in medical device and pharmaceutical manufacturing, offering vertically integrated capabilities from ideation to volume production. Key offerings include precision molding, complex extrusions, catheters, hypotubes, drug and hydrophilic coatings, and smart medical devices with sensor integration. They operate 12 manufacturing sites worldwide with ISO 13485 certified and FDA registered facilities across Americas, Europe, and Asia.

FUJIFILM Irvine Scientific (now FUJIFILM Biosciences Inc.) is a global leader in manufacturing cell culture media, reagents, and medical devices for biopharmaceuticals, cell and gene therapy, regenerative medicine, vaccines, and assisted reproductive technology. The company operates cGMP facilities in California, USA, and Tokyo, Japan, adhering to ISO and FDA regulations. It supports large-scale biotherapeutic production with innovative tools like automated media preparation systems and AI-driven media development.

BioSpring is a GMP oligonucleotide CDMO providing end-to-end manufacturing services for RNA therapeutics, from early discovery through commercial-scale production. The company specializes in solid-phase synthesis, analytical development, and cGMP-compliant manufacturing of antisense, siRNA, aptamers, and other oligonucleotide therapeutics. BioSpring supports pharmaceutical companies in scaling complex molecules while ensuring regulatory compliance with FDA, EMA, and ICH guidelines.

Just - Evotec Biologics is a CDMO providing end-to-end development and cGMP manufacturing for antibodies, next-generation biologics, and biosimilars. They specialize in continuous manufacturing technology to reduce costs and improve access to affordable biotherapeutics, with facilities in Seattle, Redmond (US), and Toulouse (France). Services span discovery using AI platforms like J.HAL and J.MD, process development, and clinical-to-commercial production up to 2,000+ kg/year.

Hydrosome Labs offers ultrafine bubble (UFB) technology, branded as Hydrosome H2O, that enhances precision fermentation by improving nutrient and gas delivery to cells. This results in 2X faster cell doubling, 25% less fermentation time, and 2X higher biomass yields without new infrastructure. Applications span pharmaceuticals, biopharma, industrial enzymes, and biomanufacturing, addressing capacity bottlenecks.

Immunexpress develops molecular diagnostics for rapid sepsis detection by analyzing host immune response gene expression from whole blood. Their flagship product, SeptiCyte RAPID, is a fully automated cartridge compatible with the Biocartis Idylla platform, delivering results in about one hour to differentiate sepsis from non-infectious inflammation. This technology supports clinicians in early triage and treatment decisions, improving patient outcomes and reducing healthcare costs.

Inscripta provides the Onyx benchtop platform for scalable CRISPR-based digital genome engineering, enabling massively parallel editing of single cells with automated workflows, consumables, software, and assays. The company also offers GenoScaler, a microbial strain engineering platform using CRISPR, AI, and machine learning for biomanufacturing applications in pharmaceuticals, agriculture, and chemicals. Headquartered in Boulder, Colorado, with offices in California and Denmark, Inscripta supports global research labs in accelerating biological discovery and strain optimization.

UCB is a global biopharmaceutical company focused on neurology and immunology, developing treatments for epilepsy, rheumatoid arthritis, and rare neurological disorders. Key products include CIMZIA® for inflammatory diseases, VIMPAT® and KEPPRA® for epilepsy, and emerging therapies like BIMZELX®, EVENITY®, FINTEPLA®, RYSTIGGO®, and ZILBRYSQ®. The company invests about a quarter of its revenue in R&D, with operations in nearly 40 countries and headquarters in Brussels, Belgium.

FUJIFILM Biosciences is a global life sciences media provider offering innovative products and contract development and manufacturing organization (CDMO) services for biopharmaceutical development and commercialization. The company operates state-of-the-art facilities across the USA, Japan, and Europe with capabilities spanning early-stage research through commercial manufacturing of therapeutics and vaccines. FUJIFILM provides redundant manufacturing capacity, quality control laboratories, and cold-chain logistics to support regulated product development with FDA and ISO compliance.

KBI Biopharma is a global CDMO providing end-to-end biologics development and manufacturing, from cell line development to commercial cGMP supply. They specialize in complex molecules like mAbs, Fc-fusions, multispecifics, and conjugates using platforms such as SUREtechnology Platform™ and PUREplatform™. Capabilities include advanced analytical characterization, process development, formulation, and state-of-the-art facilities with 10 x 2,000L single-use bioreactors.

SCIEX provides mass spectrometry, capillary electrophoresis (CE), liquid chromatography (LC), and software solutions for life sciences and pharmaceutical research. Their technologies enable precise detection, quantitation, and analysis of molecules in omics, biomarker discovery, and biomedical applications. SCIEX supports end-to-end workflows to accelerate scientific discovery and improve lab productivity.

MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, provides comprehensive products and services for pharmaceutical development, biomanufacturing, and analytical testing. The company offers single-use technologies, filtration systems, protein standards, quality control software, and consultative services to optimize complex life science workflows. With significant global capacity investments and innovative solutions like M-Trace sterility testing software, MilliporeSigma supports pharmaceutical manufacturers from research through manufacturing and quality assurance.

Miltenyi Biotec provides research- and clinical-grade products for sample preparation, cell separation, flow cytometry, and cell culture. Miltenyi Bioindustry, its CDMO division, offers services for developing and manufacturing cell and gene therapies, including lentiviral vectors, from preclinical to commercial scale. The company supports immunotherapy, regenerative medicine, and graft engineering with automated systems like CliniMACS Prodigy.

TriLink BioTechnologies, part of Maravai LifeSciences, is a leading CDMO specializing in nucleic acid synthesis, including mRNA, oligonucleotides, plasmids, NTPs, and mRNA capping analogs like proprietary CleanCap® technology. They provide scalable manufacturing from research-grade (RUO) to full cGMP for therapeutic, vaccine, and diagnostic applications, with expertise in process development, scale-up, and technology transfer. Operating from a 118,000 sq. ft. facility in San Diego's Sorrento Valley, TriLink supports biopharma from early research to commercial production.

Multiply Labs develops cloud-controlled modular robotic systems that automate biomanufacturing for cell and gene therapies, integrating with GMP instruments for high-throughput production. These systems enable scalable manufacturing of personalized therapies in pharma facilities, reducing costs by up to 74% and minimizing contamination risks. They collaborate with leaders like AstraZeneca, Thermo Fisher, and NVIDIA to deploy robotics in cleanrooms for precision medicine.

Leon Nanodrugs is a Munich-based technology provider specializing in nanoparticle-based drug manufacturing equipment and services. The company offers proprietary FR-JET mixing reactor systems and a portfolio of devices (NANOlab, NANOme, NANOus) that enable seamless scaling from R&D to GMP-compliant commercial manufacturing. Leon's platform supports nanoencapsulation of active pharmaceutical ingredients, RNA-based lipid nanoparticles, and genetic material delivery systems, with integrated aseptic processing for personalized and commercial-scale production.

EXO Biologics is a Belgian clinical-stage biotech company developing exosome-based biopharmaceuticals for rare diseases with high unmet needs, including respiratory conditions like bronchopulmonary dysplasia (BPD) in preterm newborns. They offer ExoXpert, a specialized CDMO service for exosome development and GMP manufacturing using the ExoPulse platform. Their pipeline targets inflammatory, neurological, and oncological applications, with lead candidate EXOB-001 in Phase 1/2 trials.

Noramco is a leading manufacturer of controlled substance active pharmaceutical ingredients (APIs), specializing in opioids, cannabinoids, and stimulants. Headquartered in Delaware, USA, the company provides DEA-compliant development and production from kilos to multi-ton scales, supporting pharmaceutical innovation with high-purity synthetic and semi-synthetic compounds. Noramco holds approvals from FDA, Health Canada, MHRA, and EMA, ensuring global regulatory compliance.

Noramco specializes in the development and cGMP manufacturing of specialty active pharmaceutical ingredients (APIs), with a focus on controlled substances including opioids, stimulants, and cannabinoids. The company offers end-to-end solutions from narcotic raw materials and intermediates to multi-ton commercial supplies, supported by DEA-compliant processes in facilities across the United States and Europe. Additional services include custom synthesis, pre-formulation studies, particle sizing, stability assessments, and supply chain integration for pharmaceutical procurement and R&D.

ORYL Photonics develops laser-based instruments for measuring solubility and aggregation of drug molecules and APIs in life sciences and pharma. Their patented light scattering technology, including the ORYL F1 platform, enables rapid, accurate, high-throughput analysis using minimal sample quantities. This Swiss EPFL spin-off supports R&D by reducing time and costs in formulation optimization.

BioSpring is a contract manufacturing organization (CMO) based in Frankfurt, Germany, specializing in therapeutic oligonucleotide and mRNA synthesis since 1997. The company provides GMP-compliant manufacturing, analytical services, and quality control for antisense, siRNA, conjugates, and long single-stranded RNA applications across preclinical, clinical, and commercial stages. BioSpring operates cGMP cleanrooms and offers both small-scale and large-scale production with advanced LC-MS workflows and compliance-ready processes.